Trial | NCT00544921  Report issue

Title

Phase 1 Study of Anti-glycation Agent GLY-230 in Healthy Subjects
Phase 1 Study of Anti-glycation Agent GLY-230

  • Phase

    Phase 1

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    gly-230 ...

  • Study Participants

    54
To test the safety of GLY-230 and to evaluate how long drug stays in blood after taking it by mouth.
Study Started
Oct 31
2005
Primary Completion
Oct 31
2006
Study Completion
Oct 31
2006
Last Update
Feb 10
2016
Estimate

Drug GLY-230

Other Placebo

No drug administered

50 mg Experimental

100 mg Experimental

250 mg Experimental

500 mg Experimental

750 mg Experimental

1000 mg Experimental

Placebo Placebo Comparator

Criteria 

Inclusion Criteria:

Men age 18-55
Negative drug screen
Normal EKG, clinical chemistries, CBC, urinalysis, and
Give written informed consent

Exclusion Criteria:

Active concomitant serious medical or surgical disease,
Hepatic or renal laboratory values above reference range, ise of other experimental drug within previous 30 days
No Results Posted